Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Teriparatide Coverage Policy Update | OpenPa…
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0330

    Bone Modifiers - Teriparatide Products

    Customize your policy alerts

    Sign up for Cigna Policy IP0330 alerts

    Get alerted when Policy IP0330 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Bonsity, Forteo, and teriparatide subcutaneous injections. It applies to Cigna-administered health benefit plans and establishes indication-specific clinical, prior-treatment, duration, and preferred-product requirements.

    Policy Summary
    PayerCigna
    PolicyBone Modifiers - Teriparatide Products
    Policy CodePolicy IP0330
    Change TypeModified
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionPrior authorization is required for benefit coverage of all teriparatide products.
    SourceLink
    POLICY UPDATE CHANGES

    Chronic hypoparathyroidism was removed as a condition of approval.

    Bonsity was added to the coverage policy and preferred-product criteria.

    Product availability descriptions for Forteo and teriparatide were updated from 600 mcg/2.4 mL to 560 mcg/2.24 mL.

    Preferred-product criteria were revised to address inactive-ingredient differences and use of the terms 'tried and cannot take.'

    An exception was added allowing individual and family plan members with glucocorticoid-induced osteoporosis to bypass the Tymlos trial requirement.

    Criteria were added for approval when patients cannot take oral bisphosphonates or have severe renal impairment.

    An exception was added allowing a postmenopausal patient with a very low T-score below -3.0 to bypass a bisphosphonate trial.

    Calcium and/or vitamin D supplements were expressly identified as permissible with teriparatide despite the concurrent-use exclusion for other osteoporosis medications.

    Acute post-surgical hypoparathyroidism and hypoparathyroidism caused by calcium-sensing receptor mutations were removed from conditions not covered.

    3Teriparatide products identified

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 yearsMaximum lifetime treatment
    12 monthsOral bisphosphonate trial
    <35 mL/minRenal impairment threshold
    PA requiredUtilization management
    T-score < -3.0Very-low-T-score exception

    Covered and Noncovered Uses

    Glucocorticoid-induced osteoporosis

    Teriparatide products are medically necessary when ONE of the following indications is met and all criteria for that indication are satisfied.

    • Qualifying prior therapy or clinical circumstance

      • Zoledronic acid trial: Patient has tried intravenous zoledronic acid (Reclast).
      • Oral bisphosphonate trial or intolerance: Patient has tried at least one oral bisphosphonate or oral bisphosphonate-containing product and has either experienced inadequate efficacy after a 12-month trial or significant intolerance.
      • Unable to take oral therapy: Patient cannot take an oral bisphosphonate because of difficulty swallowing, inability to remain upright after administration, or a preexisting gastrointestinal condition.
      • Renal impairment or fracture

        • According to the prescriber, patient has severe renal impairment or chronic kidney disease.Example: creatinine clearance < 35 mL/minute
        • Patient has had an osteoporotic fracture or fragility fracture.
    • Fracture-risk and duration

      • High fracture risk: If the patient is at high risk for fracture and is initiating therapy or has received a teriparatide product for less than 1 year, approve for up to 2 years total lifetime therapy; if the patient has already received at least 1 year, approve for 1 year. Use beyond 2 years is evaluated annually for continued high fracture risk.Maximum 2 years total lifetime treatment
      • Not at high fracture risk: If the patient is not at high risk for fracture, approve only for the duration necessary to complete a maximum of 2 years of total lifetime therapy.Maximum 2 years total lifetime treatment
    • Product criterion: Applicable non-covered or preferred-product criteria are met as directed in the product table.

    Postmenopausal osteoporosis

    Approve for the indicated duration when ALL criteria A-D are met.

    • A. Qualifying skeletal condition

      • Current or historical T-score is at or below 2.5 at the lumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist).T-score at or below 2.5
      • Patient has had an osteoporotic fracture or fragility fracture.
      • Low bone mass and high fracture risk: Patient has low bone mass and, according to the prescriber, is at high risk for fracture.Low bone mass: T-score between -1.0 and -2.5
    • B. Qualifying prior therapy or exception

    Primary or hypogonadal osteoporosis in men

    Approve for the indicated duration when ALL criteria A-D are met.

    • A. Qualifying skeletal condition

      • Current or historical T-score is at or below 2.5 at the lumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist).T-score at or below 2.5
      • Patient has had an osteoporotic fracture or fragility fracture.
      • Low bone mass and high fracture risk: Patient has low bone mass and, according to the prescriber, is at high risk for fracture.Low bone mass: T-score between -1.0 and -2.5
    • B. Qualifying prior therapy or exception

    Duration and continuation therapy

    Continuation approval is based on cumulative prior teriparatide exposure and fracture risk.

    Continuation duration

    • High fracture risk and less than 1 year of prior therapy: If the patient remains at high risk for fracture and has received less than 1 year of teriparatide, approve only through completion of 2 years total lifetime therapy.Maximum 2 years total lifetime therapy
    • High fracture risk and at least 1 year of prior therapy: If the patient remains at high risk for fracture and has already received at least 1 year of teriparatide, approve for 1 year. Use beyond 2 years is evaluated annually for continued high fracture risk.
    • Not at high fracture risk: If the patient is not at high risk for fracture, approve only for the remaining duration necessary to complete a maximum of 2 years of total lifetime therapy.Maximum 2 years total lifetime therapy

    Employer-plan preferred products

    For employer plans, the patient must meet the underlying coverage criteria and the product-specific requirement below.

    Bonsity 560 mcg/2.24 mL teriparatide: Patient has tried teriparatide 560 mcg/2.24 mL subcutaneous injection.
    Forteo 560 mcg/2.24 mL teriparatide: Patient has tried teriparatide 560 mcg/2.24 mL subcutaneous injection, the bioequivalent generic, and cannot continue it because of a formulation difference in inactive ingredients that, according to the prescriber, would result in a significant allergy or serious adverse reaction.

    Inactive ingredients may include dyes, fillers, or preservatives.

    Teriparatide 620 mcg/2.48 mL by Alvogen: Patient has tried teriparatide 560 mcg/2.24 mL subcutaneous injection, the bioequivalent product, and cannot continue it because of a formulation difference in inactive ingredients that, according to the prescriber, would result in a significant allergy or serious adverse reaction.

    Inactive ingredients may include dyes, fillers, or preservatives.

    Individual and family plan preferred products

    For individual and family plans, the patient must meet the underlying coverage criteria and ONE applicable exception.

    Product-specific exception

    • Patient has tried and cannot take Tymlos (abaloparatide) subcutaneous injection.

      Tymlos may require prior authorization.

    • Glucocorticoid-induced osteoporosis exception: Patient has glucocorticoid-induced osteoporosis (GIO).

      This exception is listed for Bonsity and teriparatide 620 mcg/2.48 mL by Alvogen; the Tymlos exception is listed for all products in the table.

    Conditions not covered

    Teriparatide products are not medically necessary for the following uses.

    • Use for osteoporosis prevention.
    • Concurrent use with other medications for osteoporosis, including oral or intravenous bisphosphonates, denosumab products, calcitonin nasal spray, Tymlos (abaloparatide), or Evenity (romosozumab-aqqg).

      Calcium and/or vitamin D supplements may be used concurrently.

    Teriparatide should be avoided in patients with an increased baseline risk of osteosarcoma. Safety information notes limited data for treatment beyond 2 years and recommends avoiding use when baseline osteosarcoma risk is elevated.

    Teriparatide products are not medically necessary for osteoporosis prevention. The products have not been studied in this population, and the benefits and risks of building bone when substantial bone loss has not occurred have not been established.

    Concurrent use of teriparatide with other osteoporosis medications is not covered. Excluded combinations include oral or intravenous bisphosphonates, denosumab products, calcitonin nasal spray, Tymlos (abaloparatide), and Evenity (romosozumab-aqqg). Calcium and/or vitamin D supplements may be used concurrently.

    Teriparatide products are considered not medically necessary for any other use not covered by the policy, including osteoporosis prevention and concurrent use with other osteoporosis medications. The list of noncovered uses may be updated as new published data become available.

    Initial Therapy and Product Selection

    Initial therapy

    Initial therapy is covered for an FDA-approved indication when ALL indication-specific requirements and the applicable product criteria are met.

    Initial therapy requirements

    • FDA-approved indication

      • Glucocorticoid-induced osteoporosis: Patient is initiating or continuing chronic systemic glucocorticoid therapy and meets the qualifying prior-therapy or exception criteria, fracture-risk and duration criteria, and applicable product criteria.
      • Postmenopausal osteoporosis: Patient is a postmenopausal woman with a qualifying T-score, osteoporotic or fragility fracture, or low bone mass with high fracture risk; meets the qualifying prior-therapy or exception criteria, fracture-risk and duration criteria, and applicable product criteria.
      • Primary or hypogonadal osteoporosis in men:

    Continuation Therapy

    Continuation and cumulative duration

    For patients continuing teriparatide, approval duration depends on cumulative prior exposure and current fracture risk.

    Continuation duration

    • High fracture risk; less than 1 year of prior therapy: Approve through the point at which the patient reaches 2 years of total lifetime teriparatide therapy.Maximum 2 years total lifetime therapy
    • High fracture risk; at least 1 year of prior therapy: Approve for 1 year. Treatment beyond 2 years is evaluated annually for continued high fracture risk.
    • Not at high fracture risk: Approve only for the remaining duration needed to complete a maximum of 2 years of total lifetime therapy.

    Required Prior Therapy and Preferred Products

    StepRequirementException
    1Before teriparatide coverage, try zoledronic acid, intravenous ibandronate where applicable, or at least one oral bisphosphonate.The requirement may be bypassed when the patient cannot take oral therapy, has significant intolerance, severe renal impairment or chronic kidney disease, or has an osteoporotic or fragility fracture.
    StepPlan and productRequirement
    2Employer plans — Bonsity, Forteo, or teriparatide 620 mcg/2.48 mL by AlvogenTry teriparatide 560 mcg/2.24 mL subcutaneous injection, identified as the bioequivalent generic, before the branded or alternative product.
    PlanStep requirementException
    Individual and family plansTry Tymlos (abaloparatide) subcutaneous injection and establish that the patient cannot take it.The Tymlos trial is not required for a patient with glucocorticoid-induced osteoporosis.
    StepApplicable productsRequirement
    1Employer plans — branded or other listed teriparatide products, including Forteo and teriparatide 620 mcg/2.48 mL by AlvogenTry teriparatide 560 mcg/2.24 mL subcutaneous injection first. The requested product may be approved when the patient cannot continue the bioequivalent product because of an inactive-ingredient formulation difference causing a significant allergy or serious adverse reaction.

    Lifetime Treatment Duration

    All teriparatide products
    Lifetime maximumMaximum of 2 years total treatment during the patient's lifetime
    Beyond two yearsTreatment beyond 2 years may be considered annually only when the patient remains at high risk for fracture
    Duration basisApproval duration accounts for cumulative prior teriparatide exposure
    Teriparatide products
    Total lifetime therapyMaximum 2 years of total therapy during the patient's lifetime
    Therapy beyond two yearsRequires annual review for continued high fracture risk
    Continuation example

    Clinical Thresholds and Duration Parameters

    Severe renal impairment
    ThresholdCreatinine clearance below 35 mL/minute
    Qualifying conditionSevere renal impairment or chronic kidney disease
    Use in criteriaMay qualify as an exception to the usual prior bisphosphonate requirement
    Inadequate oral bisphosphonate efficacy
    Required trialAt least one oral bisphosphonate must be tried
    Inadequate efficacy duration12 months
    Examples of inadequate efficacyOngoing and significant loss of bone mineral density, lack of a bone mineral density increase, and/or an osteoporotic or fragility fracture

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of all teriparatide products. Approvals are issued for the applicable duration described in the policy.

    Documentation Required

    Specialist Requirement for Hypoparathyroidism

    For hypoparathyroidism, teriparatide must be prescribed by, or provided in consultation with, a physician who specializes in the condition being treated. The specialist requirement supports evaluation, diagnosis, adverse-event monitoring, and assessment of long-term efficacy.

    Prior Authorization

    Plan-Specific Prior Authorization Criteria

    Therapeutic Context

    Teriparatide products are parathyroid hormone (PTH 1-34) analogs that increase bone formation. The policy addresses selected treatment of osteoporosis, including glucocorticoid-induced osteoporosis, postmenopausal osteoporosis, and primary or hypogonadal osteoporosis in men, generally for patients at high fracture risk or who have failed or cannot tolerate other osteoporosis therapy.

    Clinical Definitions and Thresholds

    High risk for fracture
    DefinitionA history of osteoporotic fractures, multiple fracture risk factors, or failure or intolerance of other osteoporosis therapy
    Representative risk factorsPrevious osteoporotic or fragility fracture, medications that increase osteoporosis risk, advanced age, and very low bone mineral density
    Very high-risk exampleA very low T-score, such as below -3.0, may indicate very high fracture risk
    Low bone mass
    T-score rangeBetween -1.0 and -2.5
    Qualifying skeletal sitesLumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist)
    Policy Summary
    PayerCigna
    PolicyBone Modifiers - Teriparatide Products
    Policy CodePolicy IP0330
    Change TypeModified
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionPrior authorization is required for benefit coverage of all teriparatide products.
    SourceLink
    On This Page
    Covered and Noncovered UsesInitial Therapy and Product SelectionContinuation TherapyRequired Prior Therapy and Preferred ProductsLifetime Treatment DurationClinical Thresholds and Duration ParametersAuthorization, Documentation, and Denial RisksTherapeutic ContextClinical Definitions and Thresholds
  1. Patient has tried intravenous ibandronate or intravenous zoledronic acid (Reclast).
  2. Patient has tried at least one oral bisphosphonate or oral bisphosphonate-containing product and has experienced inadequate efficacy after a 12-month trial or significant intolerance.
  3. Patient cannot take an oral bisphosphonate because of difficulty swallowing, inability to remain upright after administration, or a preexisting gastrointestinal condition.
  4. Renal impairment, fracture, or very low T-score

    • According to the prescriber, patient has severe renal impairment or chronic kidney disease.Example: creatinine clearance < 35 mL/minute
    • Patient has had an osteoporotic fracture or fragility fracture.
    • Patient has a very low T-score.T-score < -3.0
  5. C. Fracture-risk duration

    • High fracture risk: If the patient is at high risk for fracture and is initiating therapy or has received a teriparatide product for less than 1 year, approve for up to 2 years total lifetime therapy; if the patient has already received at least 1 year, approve for 1 year. Use beyond 2 years is evaluated annually for continued high fracture risk.Maximum 2 years total lifetime treatment
    • Not at high fracture risk: If the patient is not at high risk for fracture, approve only for the duration necessary to complete a maximum of 2 years of total lifetime therapy.Maximum 2 years total lifetime treatment
  6. D. Preferred product: Preferred-product criteria are met for the requested product as listed in the applicable table.
  7. Patient has tried intravenous zoledronic acid (Reclast).
  8. Patient has tried at least one oral bisphosphonate or oral bisphosphonate-containing product and has experienced inadequate efficacy after a 12-month trial or significant intolerance.
  9. Patient cannot take an oral bisphosphonate because of difficulty swallowing, inability to remain upright after administration, or a preexisting gastrointestinal condition.
  10. Renal impairment or fracture

    • According to the prescriber, patient has severe renal impairment or chronic kidney disease.Example: creatinine clearance < 35 mL/minute
    • Patient has had an osteoporotic fracture or fragility fracture.
  11. C. Fracture-risk duration

    • High fracture risk: If the patient is at high risk for fracture and is initiating therapy or has received a teriparatide product for less than 1 year, approve for up to 2 years total lifetime therapy; if the patient has already received at least 1 year, approve for 1 year. Use beyond 2 years is evaluated annually for continued high fracture risk.Maximum 2 years total lifetime treatment
    • Not at high fracture risk: If the patient is not at high risk for fracture, approve only for the duration necessary to complete a maximum of 2 years of total lifetime therapy.Maximum 2 years total lifetime treatment
  12. D. Preferred product: Preferred-product criteria are met for the requested product as listed in the applicable table.
  13. Patient is a man with primary or hypogonadal osteoporosis and a qualifying T-score, osteoporotic or fragility fracture, or low bone mass with high fracture risk; meets the qualifying prior-therapy or exception criteria, fracture-risk and duration criteria, and applicable product criteria.
  14. Qualifying prior therapy or exception

    • Patient has tried intravenous zoledronic acid, or intravenous ibandronate where applicable.
    • Patient has tried at least one oral bisphosphonate and had inadequate efficacy after 12 months or significant intolerance.
    • Patient cannot take an oral bisphosphonate because of swallowing difficulty, inability to remain upright, or a preexisting gastrointestinal condition.
    • Other listed exception

      • Patient has severe renal impairment or chronic kidney disease.Example: creatinine clearance < 35 mL/minute
      • Patient has had an osteoporotic or fragility fracture.
      • For postmenopausal osteoporosis, patient has a very low T-score.T-score < -3.0
  15. Initial approval duration

    • High fracture risk and less than 1 year of prior teriparatide: Approve up to 2 years total lifetime therapy.
    • High fracture risk and at least 1 year of prior teriparatide: Approve for 1 year; use beyond 2 years is evaluated annually for continued high fracture risk.
    • Not at high fracture risk: Approve only for the duration necessary to complete a maximum of 2 years total lifetime therapy.
  16. Product preference: Applicable employer-plan or individual-and-family-plan product criteria are met.

    Prior authorization is required for all teriparatide products.

  17. Employer-plan initial product selection

    For employer plans, the patient must meet the underlying policy criteria and the applicable product hierarchy requirement.

    Employer-plan product selection

    • Bonsity 560 mcg/2.24 mL: Patient has tried teriparatide 560 mcg/2.24 mL subcutaneous injection.
    • Forteo 560 mcg/2.24 mL: Patient has tried teriparatide 560 mcg/2.24 mL subcutaneous injection, the bioequivalent generic, and cannot continue it because of an inactive-ingredient formulation difference causing a significant allergy or serious adverse reaction.
    • Teriparatide 620 mcg/2.48 mL by Alvogen: Patient has tried teriparatide 560 mcg/2.24 mL subcutaneous injection, the bioequivalent product, and cannot continue it because of an inactive-ingredient formulation difference causing a significant allergy or serious adverse reaction.

    Individual and family plan initial product selection

    For individual and family plans, the patient must meet the underlying policy criteria and ONE applicable product exception.

    Individual and family plan product selection

    • Tymlos trial: Patient has tried and cannot take Tymlos (abaloparatide) subcutaneous injection.
    • Glucocorticoid-induced osteoporosis exception: Patient has glucocorticoid-induced osteoporosis (GIO), where the product table permits bypass of the Tymlos trial requirement.
    Maximum 2 years total lifetime therapy

    Continuation and lifetime duration

    Approve continuation according to prior teriparatide exposure and fracture risk.

    • At least 1 year of prior therapy and high fracture risk: Approve for 1 year; use beyond 2 years of total lifetime therapy requires annual evaluation for continued high fracture risk.
    • Less than 1 year of prior therapy and high fracture risk: Approve only through completion of 2 years of total lifetime therapy.Maximum 2 years total lifetime therapy
    • Not at high fracture risk: Approve only for the time necessary to complete 2 years of total lifetime therapy.Maximum 2 years total lifetime therapy
    After at least 1 year of prior teriparatide therapy, approval may be for 1 year
    Osteoporosis or low bone mass
    Osteoporosis thresholdT-score at or below 2.5
    Qualifying skeletal sitesLumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist)
    Low bone mass thresholdT-score between -1.0 and -2.5 at a qualifying skeletal site
    Very low T-score
    Very low T-scoreBelow -3.0
    Measurement contextT-score may be current or have been recorded at any time in the past
    Clinical significanceListed as an exception in the qualifying prior therapy criteria for postmenopausal osteoporosis
    Lifetime teriparatide treatment
    Lifetime maximumMaximum of 2 years total during the patient's lifetime
    High fracture riskIf high fracture risk persists, use beyond 2 years is evaluated annually
    Lower-risk durationIf the patient is not at high fracture risk, approve only the duration needed to complete 2 years total lifetime therapy
    Very low T-score exception
    Exception thresholdVery low T-score below -3.0
    Requirement bypassedThe patient may bypass a bisphosphonate trial
    Applicable indicationPostmenopausal osteoporosis treatment

    Document the underlying approved indication and satisfy the applicable plan-specific preferred-product criteria before requesting authorization. Criteria differ between employer plans and individual and family plans.

    • Include the indication-specific clinical criteria supporting treatment.
    • Apply the product-step requirements for the patient's plan type.

    Unsupported block type: step_therapy

    Unsupported block type: step_therapy

    Unsupported block type: step_therapy

    Unsupported block type: step_therapy

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: step_therapy

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Denial Risk

    Clinical Criteria Not Met

    Authorization may be denied when the patient does not satisfy the indication-specific clinical criteria, including the required diagnosis, fracture-risk findings, therapy status, or other criteria for the requested indication.

    • Confirm all required criteria are documented before submission.
    • Criteria differ for glucocorticoid-induced osteoporosis, postmenopausal osteoporosis, and osteoporosis in men with primary or hypogonadal osteoporosis.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Additional requirement
    For coverage based on low bone mass, the prescriber must consider the patient at high risk for fracture
    Severe renal impairment
    Example thresholdCreatinine clearance below 35 mL/minute
    Clinical conditionSevere renal impairment or chronic kidney disease
    Coverage relevanceMay support an exception to oral bisphosphonate therapy requirements
    Glucocorticoid-induced osteoporosis
    DefinitionOsteoporosis caused or associated with glucocorticoid therapy
    Associated therapySustained systemic glucocorticoid therapy, such as a daily dosage equivalent to 5 mg or greater of prednisone
    Covered populationMen and women at high risk for fracture